Screener
Vertex Pharmaceuticals VRTX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's EBITDA margin?
- Vertex Pharmaceuticals (VRTX) reported EBITDA margin of 40.1% in Q1 2026.
- How has Vertex Pharmaceuticals's EBITDA margin changed year-over-year?
- Vertex Pharmaceuticals's EBITDA margin increased by 1142.5% year-over-year, from -3.8% to 40.1%.
- What is the long-term trend for Vertex Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's EBITDA margin has grown at a -5.2% compound annual growth rate (CAGR), from 47.8% to 36.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Vertex Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude